Asthma Clinical Trial
To identify susceptibility genes associated with asthma and asthma related phenotypes.
BACKGROUND:
Asthma is an increasingly common disease caused by bronchial inflammation and characterized
by bronchial hyperresponsiveness and intermittent airways obstruction. The development of
asthma is most likely determined by an interaction between host susceptibility and
environmental exposures. Bronchial hyperresponsiveness (BHR) and elevated total serum IgE
levels, characteristic findings in asthma, have been shown to have strong genetic
components. The identification of the genetic factors that regulate susceptibility to asthma
has important public health consequences, and may lead to an improved understanding of the
pathogenesis of asthma. This may lead to improved preventive measures and new therapeutic
approaches.
The study is in response to a Request for Applications on "Positional Candidate Gene
Approaches in Asthma Gene Discovery" issued in October 1999.
DESIGN NARRATIVE:
In an effort to delineate genetic susceptibility to asthma, Dr. Bleecker and colleagues have
identified several regions of the genome that contain potential asthma susceptibility genes
using a Dutch population of 200 families ascertained through a proband with asthma. The two
regions with the strongest evidence for linkage after completing a genome screen were
located on chromosomes 3p14-p21 and 5q31. They will identify the asthma susceptibility gene
located on chromosome 3p using the Dutch families and determine its contribution to this
disease in other populations. There are six specific aims in the study. The first is to
develop a high-resolution genetic map of the candidate region on chromosome 3p14-p21. The
second aim is to construct a correlated genetic and physical map of the candidate region on
chromosome 3p. The third aim is to genotype an additional cohort of Dutch trios (one
affected child and both parents) to identify haplotypes and to confirm case-control
candidate gene studies. The fourth aim is to analyze known and novel genes from the
candidate region using a case-control study design in the same population. The fifth aim is
to determine the contribution of the chromosome 3p asthma susceptibility gene in other
populations including the U.S. Collaborative Study for the Genetics of Asthma (CSGA) and Dr.
Ober's Hutterite population. The sixth aim is to characterize the identified single
nucleotide polymorphism (SNP) or haplotype that contributes to asthma susceptibility. There
will be interaction with other investigators to determine the impact of each genetic locus
and to investigate gene-gene interactions.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|